Q&A: How Does BioEngine Navigate The Tariff War With Ease?

Recent tariff policy adjustments have been frequent, and many friends have sent us private messages asking: Will the supply of cell culture media be affected? Today, Panda will address several key questions of concern to our customers.

Q: I heard that most raw materials for culture media are imported. Will tariffs impact your products?

A: There is absolutely no need to worry! As early as 2016, we launched a strategic initiative to source, test, and validate domestic raw materials. After more than 5 years of dedicated efforts, we established a rigorous "2+1" raw material supply model-meaning each raw material is supplied by 2 domestic suppliers plus 1 international supplier simultaneously. Currently, over 95% of BioEngine's raw materials adopt this "2+1" supply model, and even some of our culture media products use 100% domestic raw materials. For the very small number of irreplaceable imported raw materials, BioEngine ensures supply chain resilience through diversified procurement channels and strategic reserve mechanisms.

Q: Will using domestic raw materials compromise the performance of your culture media?

A: Actually, the performance of a culture medium depends on multiple factors, including formula design, raw material quality, production processes, quality control, and product application scenarios. Specifically for raw materials, we have a three-tier quality control mechanism in place to ensure reliability:

Screening raw material suppliers in accordance with GMP guidelines;

Selecting suitable raw materials based on medium formulas and material characteristics;

Conducting rigorous testing of key attributes on every batch of raw materials (meeting standards higher than pharmacopoeial or industry requirements).

BioEngine's culture media have earned widespread market recognition. We have served over 400 corporate clients and supported numerous pharmaceutical companies in achieving critical breakthroughs. For example, in one antibody biosimilar project, our medium helped boost production yield by 6-fold while ensuring product quality matched that of the reference drug.

Q: How do you ensure product quality stability?

A: Quality is our lifeline. BioEngine has obtained ISO 13485:2016 and MDSAP (FDA) international quality system certifications. We adopt the same cone mixing and pin milling powder production process as world-leading brands, ensuring exceptional batch-to-batch consistency (with RSD < 5% and Cpk ≥ 1.33). To date, we have successfully completed the production of over 1,000 batches of powder media.

Q: If order volumes surge in the short term, can Bainaji's production capacity keep up without delaying delivery times?

A: We operate 4 powder culture media production lines and 2 liquid culture media production lines. The maximum single-batch capacity of powder media reaches 100,000 liters, with an annual production capacity of 55 million liters for powder media and 250,000 liters for liquid media-fully capable of meeting customers' urgent scale-up demands. Through intelligent production and flexible supply chain management, we guarantee on-time order delivery and fully support the progress of major biopharmaceutical projects in China.

Taking the Challenging yet Right Path of "China Smart Manufacturing" to Navigate Trade Frictions with Confidence

BioEngine firmly believes that the localization of culture media should embody the essence of "China Smart Manufacturing"-leveraging abundant domestic raw materials, possessing strong independent R&D and innovation capabilities, and adhering to internationally advanced production and quality management standards.

Going forward, BioEngine will continue to take the challenging yet right path of "China Smart Manufacturing." We will strive to conquer core key technologies in cell culture, build a safe and efficient supply chain system, continuously enhance product competitiveness and supply security capabilities, effectively support customers in achieving steady development in the biopharmaceutical field, and help China's biopharmaceutical industry gain greater voice on the global stage.